Drug intelligence / Profile preview

glofitamab + polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone

Development stage: Unknown
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

This combination regimen is a multi-drug chemo-immunotherapy being investigated for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL). It integrates three distinct targeted biological agents with a modified chemotherapy backbone. **Glofitamab** is a bispecific T-cell engager (BiTE) that binds to CD20 on B-cells and CD3 on T-cells, inducing T-cell mediated cytotoxicity. **Polatuzumab vedotin** is an antibody-drug conjugate (ADC) targeting CD79b, delivering the microtubule inhibitor monomethyl auristatin E (MMAE) directly to malignant B-cells. **Zuberitamab** is a recombinant humanized anti-CD20 monoclonal antibody that promotes B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The regimen is often administered in a response-adapted manner, where patients not achieving a complete response (CR) after initial cycles receive the addition of **CHP** (cyclophosphamide, doxorubicin, and prednisone) chemotherapy. This approach aims to maximize efficacy by targeting multiple B-cell antigens and leveraging both immune-mediated and cytotoxic mechanisms of action.

Other names: Glofitamab + Polatuzumab Vedotin + Zuberitamab + CHPGlofitamab + Polatuzumab Vedotin + Zuberitamab + Cyclophosphamide + Doxorubicin + Prednisone

Targets

CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on glofitamab + polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glofitamab + polatuzumab vedotin + zuberitamab + cyclophosphamide + doxorubicin + prednisone.

Explore the full profile